Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Centre de référence constitutif des maladies pulmonaires rares Orphalung, Lille, France
Auto-generated profile, based on publicly available information
Victor Valentin
Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Centre de référence constitutif des maladies pulmonaires rares Orphalung, Lille, France
Background: Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step therapies while rituximab is used as rescue therapy.Methods: In a randomised, double-blind, two-parallel group, placebo-controlled trial (NCT02990286), patients with connective tissue disease-associated ILD or idiopathic interstitial pneumonia (with or without autoimmune features) and a NSIP pattern (defined on NSIP pathological pattern or on integration of clinicobiological data and a NSIP-like high-resolution computed tomography pattern) were randomly assigned in a 1:1 ratio to receive rituximab (1000 mg) or placebo on day 1 and day 15 in addition to MMF (2 g daily) for 6 months. The primary end-point was the change in percent predicted forced vital capacity (FVC) from baseline to 6 months analysed by a linear mixed model for repeated measures analysis. Secondary end-points included progression-free survival (PFS) up to 6 months and safety.Findings: Between January 2017 and January 2019, 122 randomised patients received at least one dose of rituximab (n=63) or placebo (n=59). The least-squares mean change from baseline to 6 months in FVC (% predicted) was +1.60 (se1.13) in the rituximab+MMF group and −2.01 (se1.17) in the placebo+MMF group (between-group difference 3.60, 95% CI 0.41–6.80; p=0.0273). PFS was better in the rituximab+MMF group (crude hazard ratio 0.47, 95% CI 0.23–0.96; p=0.03). Serious adverse events occurred in 26 (41%) patients of the rituximab+MMF group and in 23 (39%) of the placebo+MMF group. Nine infections were reported in the rituximab+MMF group (five bacterial infections, three viral infections, one other) and four bacterial infections in the placebo+MMF group.Interpretation: Combination of rituximab and MMF was superior to MMF alone in patients with ILD and a NSIP pattern. The use of this combination must take into consideration the risk of viral infection.
Background: Our objective was to evaluate the short-, medium- and long-term benefits of home-based pulmonary rehabilitation (PR) on the physical and affective components of dyspnoea in people with fibrotic idiopathic interstitial pneumonias (f-IIPs). Anxiety and depressive symptoms, fatigue, health-related quality of life and exercise tolerance were also assessed. Methods: Data on 166 individuals with f-IIPs who enrolled in an 8-week home-based PR programme (weekly supervised 90-min session) were retrospectively analysed. Assessments included the Dyspnoea-12 (D-12) questionnaire, Hospital Anxiety and Depression Scale, Fatigue Assessment Scale, Visual Simplified Respiratory Questionnaire and 6-min stepper test, and were performed at home at short, medium (6 months) and long (12 months) term. Results: Among the 166 individuals with f-IIPs who enrolled in PR, 75 (45%) and 91 (55%) participants had a diagnosis of idiopathic pulmonary fibrosis and fibrosing non-specific interstitial pneumonia, respectively, and 87 (52%) participants concluded a full year of follow-up. In the total group, both physical and affective components of dyspnoea were improved, at short, medium and long term, after PR. Overall, half of the participants reached the minimally important difference of 3 points of the D-12 questionnaire at the end of PR, and at the 6- and 12-month follow-ups. Anxiety and depressive symptoms, fatigue and health-related quality of life were also improved, while the short-term benefits in exercise tolerance were not maintained 1 year after PR. Conclusion: An individualised home-based PR programme resulted in short-, medium- and long-term improvements in both physical and affective components of dyspnoea assessed by the D-12 questionnaire.
Background: Pulmonary hypertension (PH) frequently complicates interstitial lung diseases (ILD), adversely affecting outcome. Identifying prognostic factors of patients with ILD-PH could facilitate early identification of patients who may benefit from PH therapy. Methods: We included patients with ILD-PH from the prospective HYPID cohort and the French National Pulmonary Hypertension Registry (2007–2022). Univariable and multivariable analyses were performed to identify predictors of 1-year mortality. Results: A total of 581 patients (mean age 69.4±9.3 years, 450 males) were analysed. ILD diagnoses were combined pulmonary fibrosis and emphysema syndrome (30.8%), idiopathic pulmonary fibrosis (29.6%), unclassifiable ILD (13.1%), and fibrotic hypersensitivity pneumonitis (10.3%). Mean pulmonary artery pressure was 40.7±9.1 mmHg, and mean pulmonary vascular resistance was 7.6 ±3.5 Wood units. Off-label PH therapy was initiated after initial evaluation in 215 patients (37%). The median transplant-free survival time was 17 months (95% CI 15.2 – not reached). Multivariable analysis identified male sex (p<0.001), functional class III (p=0.003) or IV (p=0.003), 6 MWD≤228 m (p5 Wood units (p=0.008), and absence of PH therapy (p<0.001) as independent predictors of death or lung transplantation at 1 year. Conclusion: Non-invasive (6 MWD, WHO FC) and invasive (PVR) variables are associated with prognosis in patients with ILD-PH, including in patients with CPFE. PH medication might improve outcomes in this patient population.
Introduction: FLNA pathogenic variants lead to various congenital malformations. Pulmonary manifestations were reported in early age. In adults, few cases of emphysema were published. We aimed to assess the frequency and characteristics of emphysema in adults with a pathogenic or probably pathogenic variant in FLNA . Method: We conducted a transversal single-center study. Adults with FLNA pathogenic variant followed in Lille University Hospital were identified among the French rare disease database BaMaRa ® . They attended medical examination, non-contrast chest CT-scan and pulmonary function tests (PFT). We collected medical history, tobacco smoking status, occupational and domestic exposures. When emphysema was identified, the PTPN6 gene was sequenced and alpha1antitrypsin deficiency searched. The primary objective of the study was to assess the frequency of emphysema. Secondary objectives were to evaluate emphysema type, distribution and extension, lung function in case of emphysema and the frequency of unexplained emphysema. Results: Among the 29 patients identified, 10 met non-inclusion criteria, 4 declined, 5 could not be reached and so 10 patients were included. The frequency of emphysema was 70%. It was most often centrilobular and located in upper lobes ( n = 4) with a median volume of 8.8% (IQR: 3.0–18.0%) of the total lung volume. The frequency of unexplained emphysema was estimated to be 57.1% of emphysema cases. PFT revealed airflow limitation ( n = 3), reduced DLCO ( n = 5) and small airway disease on IOS ( n = 5). Conclusion: These preliminary results suggest that adults with FLNA pathogenic variant frequently develop emphysema, allowing for a larger study to be considered. Trial registration: ClinicalTrials.gov, NCT05550844, Registered 19 September 2022 https://clinicaltrials.gov/study/NCT05550844?cond=FLNA&rank=1 .